CN101829148B - Traditional Chinese medicine extractive, oral preparation containing extractive and method for preparing oral preparation - Google Patents
Traditional Chinese medicine extractive, oral preparation containing extractive and method for preparing oral preparation Download PDFInfo
- Publication number
- CN101829148B CN101829148B CN2009100797605A CN200910079760A CN101829148B CN 101829148 B CN101829148 B CN 101829148B CN 2009100797605 A CN2009100797605 A CN 2009100797605A CN 200910079760 A CN200910079760 A CN 200910079760A CN 101829148 B CN101829148 B CN 101829148B
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- extract
- extractive
- oral preparation
- medicine extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Abstract
The invention relates to a traditional Chinese medicine extractive, an oral preparation containing the extractive and a method for preparing the oral preparation. The traditional Chinese medicine extractive, using leech and earthworm as raw materials, is prepared by the following method: (1) the raw materials comprise 1-100 parts by weight of leech and 1-100 parts by weight of earthworm; (2) taking leech and earthworm according to the weight parts, extracting for 1-3 times with 4-12 fold (relative to total weight of leech and earthworm) of 50-95% ethanol (V/V concentration), 1-3h each time, filtering, recycling the filter, and concentrating to obtain dry-ointment. The extractive is easier to absorb to passes through the blood brain barrier and has better curative effect. The oral preparation reduces the dosage of auxiliary material to a maximum extent, reduces the dosage of patients, saves the cost and has better curative effect for treating diseases such as cerebral apoplexy and cardiovascular diseases and the like.
Description
Technical field
The present invention relates to a kind of drug extract, particularly relate to a kind of Chinese medicine extract, comprise the preparation method of the oral formulations and the said preparation of this extract.
Background technology
Current, be the cardiovascular and cerebrovascular disease serious harm human health of representative with hypertension, apoplexy and coronary heart disease, be called as " the No.1 executioner of human health ".The quantity of cardiovascular and cerebrovascular disease increases absolute and relatively, cardiovascular and cerebrovascular disease has become first cause of the death of China urban and rural residents gradually, nearly 40% dead person dies from this class disease at present, and cardiovascular and cerebrovascular disease has become the main cause that threatens human health.
In the various cardiovascular and cerebrovascular vessel medicines of China, oral formulations mainly contains FUFANG DANSHEN DIWAN, Tongxinluo, BUCHANG NAOXINTONG, DIAOXINXUE KANG, SUXIAO JIUXIN WAN, MAILUONING, Heart pill of Musk, Fructus Pruni drop pills etc. at present.These medicines are many to be the Therapeutic Principle with the blood circulation promoting and blood stasis dispelling, adopts medical materials such as Chinese medicine such as Radix Salviae Miltiorrhizae, Folium Ginkgo, Rhizoma Chuanxiong more.But cardiovascular disease cause of disease complexity, non-simple blood circulation promoting and blood stasis dispelling can be treated.
Traditional mode dosage is big, and oral being not easy absorbs, and drug effect can not be guaranteed fully that this kind has overcome the defective of traditional medication, reforms on the basis that guarantees drug effect and innovates.
Summary of the invention
The object of the present invention is to provide a kind of Chinese medicine extract for the treatment of apoplexy and cardiovascular disease.
Another object of the present invention provides the oral formulations that comprises this extract and the preparation method of said preparation.
Chinese medicine extract of the present invention, selecting Hirudo and Pheretima for use is crude drug, this extract is prepared by following method:
1) weight proportion of crude drug: Hirudo 1-100 part, Pheretima 1-100 part;
2) press weight portion water intaking trematodiasis, the Pheretima of crude drug, doubly measure (with respect to the gross weight of Hirudo and Pheretima), each 1-3h, extract 1-3 time respectively, filter with 50-95% ethanol (volumetric concentration), 4-12, recovery filtrate, concentrated, get dry extract.
Preferably, described extract is prepared by following method:
1) weight proportion of crude drug: 50 parts of Hirudos, 50 parts of Pheretimas;
2) get Hirudo, the Pheretima of above-mentioned weight portion,, extracts 2 times, filter, reclaim filtrate with 70% ethanol (V/V), 10 times of amounts (with respect to the weight of Hirudo or Pheretima), each 1.5h, concentrated, get dry extract.
The present invention also provides the oral formulations that comprises above-mentioned Chinese medicine extract, and it comprises the component of following weight ratio: dried cream: microcrystalline Cellulose: starch is 6: 3: 1.
The oral formulations of Chinese medicine extract of the present invention can be capsule, granule, tablet, soft capsule, drop pill, oral cavity disintegration tablet, chewable tablet, peroral dosage forms such as dispersible tablet.
The present invention also provides the preparation method of Chinese medicine extraction composition oral preparation of the present invention, comprises the steps: dried cream powder and microcrystalline Cellulose, starch are mixed by proportioning, uses the ethanol moistening, makes soft material, granulates with suitable mesh sieve.
Chinese medicine composition of the present invention is monarch drug with the Hirudo, and its flavor of duty becomes second nature flat, becomes to walk blood by softening the hard mass, and is good at removing blood stasis.As far back as Shennong's Herbal just claim its " main by stagnant blood, blood stasis, the moon closes, the removing blood stasis abdominal mass is gathered, loss of fecundity, dredging water passages ".Pheretima is a minister, and this taste becomes second nature cold, is good at walking to scurry, and is heat clearing away, the medicine commonly used of disperse blood stasis and dredge collateral." book on Chinese herbal medicine is looked for the truth " cloud: " Lumbricus originally have bore soil can; the power of chemical medicine; and all fall pounce on injured; blood stasis meridians; be equipped with again and let alone to stop holding and do not digest for it " " Chinese medicine voluminous dictionary ", " national Chinese herbal medicine compilation " and " herbal pharmacology and application " all put down in writing Pheretima and can control " hemiplegia ", and claim its " blood pressure lowering, Shujin is controlled network ".Hirudo mainly contains protein, hirudin, heparin, antithrombotic element, and its secretions contains a kind of H-subst in addition, contains various trace elements such as tens seed amino acids and Zn, Mn, Fe, Co, Cr, Se, Mo and Ni in addition.Contain multiple unsaturated fatty acids such as protein, abundant enzyme, succinic acid, 20 kinds of free amino acids, nucleotide or the like in the Pheretima, therefore, need effective ingredient to be extracted just fully it and can reach good effect.
Extract of the present invention and preparation have following beneficial effect:
1, the alcohol reflux by 70% concentration extracts, this and traditional decocting boil mode and directly crude drug pulverize and be used as medicine by very big difference, simultaneously, the effective ingredient that is obtained is also different, liposoluble substance accounts for the overwhelming majority, extracts by pure hot reflux, and the macromolecular substances that major part can not oral absorption might split into small molecule segment, therefore easier absorption can play better therapeutic by blood brain barrier;
2, on prescription screening, in order to reduce the consumption of adjuvant, the present invention has abandoned the method that the big powder of medical material residue that traditional employing extracted is done adjuvant, and suitable employing more meet the chemical adjuvant of fat-soluble medicine character, by test, farthest reduce the consumption of adjuvant, reduced patient's taking dose, also saved cost;
3, on dosage form design, also fully take into account the characteristics of medicine, and the stability of product, economy, the convenience of taking etc. adopt the oral formulations that more meets with pharmaceutical properties, preferred capsule preparations;
4, the disease to aspects such as apoplexy and cardiovascular has excellent curative.
Description of drawings
Granule moisture absorption percentage rate under the different relative humiditys of No. 4 samples of Fig. 1;
Granule moisture absorption percentage rate under the different relative humiditys of No. 6 samples of Fig. 2;
Granule moisture absorption percentage rate under the different relative humiditys of No. 7 samples of Fig. 3.
The specific embodiment
Following examples are used to illustrate the present invention, but are not used for limiting the scope of the invention.
Embodiment 1
The preparation method of Chinese medicine extract of the present invention is as follows: water intaking trematodiasis, each 50g of Pheretima, extract 2 times with 500g, 70% ethanol (volumetric concentration), and each 1.5h filters, and reclaims filtrate, concentrates, and gets dry extract.
Embodiment 2
The preparation method of Chinese medicine extract of the present invention is as follows: water intaking trematodiasis 1g, Pheretima 100g, extract 1 time with 450g, 50% ethanol (volumetric concentration), and each 1h filters, and reclaims filtrate, concentrates, and gets dry extract.
Embodiment 3
The preparation method of Chinese medicine extract of the present invention is as follows: water intaking trematodiasis 100g, Pheretima 1g, extract 3 times with 1000g, 95% ethanol (volumetric concentration), and each 3h filters, and reclaims filtrate, concentrates, and gets dry extract.
Embodiment 4
The preparation method of Chinese medicine extract of the present invention is as follows: water intaking trematodiasis, each 50g of Pheretima, extract 2 times with 1200g, 80% ethanol (volumetric concentration), and each 2h filters, and reclaims filtrate, concentrates, and gets dry extract.
Embodiment 5
Chinese medicine preparation of the present invention prepares by the following method: dried cream powder (obtaining according to embodiment 1 method) 6g and microcrystalline Cellulose 3g, the starch 1g that will cross No. 4 sieves mix, and use the ethanol moistening, make soft material, granulate with 10 mesh sieves, 8 mesh sieve granulate, 65 mesh sieves remove fine powder, get granule.
Embodiment 6
Chinese medicine preparation of the present invention prepares by the following method: dried cream powder (obtaining according to embodiment 1 method) 6g and microcrystalline Cellulose 3g, the starch 1g that will cross No. 4 sieves mix, and use the ethanol moistening, make soft material, and the 18-22 mesh sieve is granulated, and is packed into capsule, gets capsule.
Embodiment 7
Chinese medicine preparation of the present invention prepares by the following method: dried cream powder (obtaining according to embodiment 1 method) 6g and microcrystalline Cellulose 3g, the starch 1g that will cross No. 4 sieves mix, and use the ethanol moistening, make soft material, and the 16-18 mesh sieve is granulated, and tabletting promptly gets tablet.
Embodiment 8
Chinese medicine preparation of the present invention prepares by the following method: will cross dried cream powder (obtaining according to the embodiment 1 method) 6g of No. 4 sieves, and with 1 part of oil with hydrogenated soybean, 1 part in Cera Flava, 4 parts of vegetable oil, 0.1% Tween 80, grind, and be pressed into soft capsule promptly.
Embodiment 9
Dried cream powder (obtaining according to the embodiment 1 method) 6g of No. 4 sieves, lactose 8g, mannitol 4g, low-substituted hydroxypropyl cellulose 4g will be crossed, microcrystalline Cellulose 3g, micropowder silica gel 0.5g, tartaric acid 0.5g, porphyrize, cross 80 mesh sieves, mix homogeneously is dissolved in an amount of 50% ethanol polyvinylpyrrolidone as binding agent, make soft material, wet granulation, 60 ℃ of air blast oven dry, after sieving, add magnesium stearate 0.3g, granulate, mixing, tabletting promptly gets oral cavity disintegration tablet.
Embodiment 10
Take by weighing PEG 4000 and PEG 6000 (2: 3 weight ratios) 18g, heating and melting added dried cream powder (obtaining according to the embodiment 1 method) 6g that sieves for No. 4, constantly stir and make fusion, be transferred to drop pill machine liquid storage tank while hot, drip 85 ℃ of system temperature, drip apart from 6cm, drip 40/min of speed, coolant is a simethicone, height 85cm, 10 ℃ of temperature are collected drop pill, inhale the coolant that goes to the drop pill surface with filter paper, drying promptly gets drop pill.
Embodiment 11
To cross dried cream powder (obtaining) 6g of No. 4 sieves, sucrose: lactose according to embodiment 1 method: mannitol (3: 1: 1 weight ratios) 18g,, be placed in the mixer by the equivalent method of progressively increasing and mix, add 1 ‰ magnesium stearate, mix homogeneously, tabletting promptly gets chewable tablet.
Embodiment 12
Dried cream powder (obtaining according to the embodiment 1 method) 6g of No. 4 sieves, carboxymethylstach sodium 2g cross-linked pvp 3g, low-substituted hydroxypropyl cellulose 4g will be crossed, microcrystalline Cellulose 4g, mixing is crossed the 100-120 mesh sieve, again with other auxiliary materials and mixing, granulate, add cross-linked pvp 2g at last, magnesium stearate 0.6g micropowder silica gel 0.4g, mixing, tabletting promptly gets dispersible tablet.
Experimental example 1 extraction process is investigated
Chinese medicine extract of the present invention is an index with hypoxanthine and pharmacodynamics when extracting, and to concentration of alcohol, ethanol consumption, extraction time is investigated.
Take by weighing Hirudo 50g, Pheretima 50g, 100g altogether, 9 parts, carry out hot reflux by table 1 and extract, put coldly, filter, merge corresponding filtrate, reclaim ethanol and be not settled to 250ml to having the alcohol flavor, concentrating.Be used for hypoxanthic mensuration, calculate and carry to such an extent that measure.The results are shown in Table 2, The results of analysis of variance sees Table 3,4.
Table 1 extraction factor water-glass
The Orthogonal experiment results that table 2 extracts
Table 3 analysis of variance table
Conclusion: factor A has appreciable impact to result of the test as shown in Table 3, and in conjunction with the drug effect result of pharmacology, therefore drug effect the best of No. 2 samples in the orthogonal test table determines that optimum extraction scheme is A
1B
2C
2Promptly 70% ethanol is measured for 10 times and is extracted each 1.5 hours.
Extraction time is investigated
Water intaking trematodiasis, each 50g of Pheretima with 70% ethanol, 10 times of amounts, 1.5h/ time, extract respectively 1,2,3 time respectively, and filtrate is reclaimed in filtration respectively, and is concentrated, is settled to 250ml, shakes up, that is, standby.With hypoxanthine content is index, determines extraction time.The results are shown in Table 4:
Table 4 extraction time is investigated
Extract as seen from the above table 2 times hypoxanthic carry amount be extract three times 92%, so, be defined as extracting 2 times in conjunction with actual big production.
Extraction process is: 70% ethanol, 10 times of amounts are extracted 2 times, each 1.5h.
Experimental example 2 oral preparation of Chinese traditional medicinal moulding processs of the present invention are investigated
1, different adjuvants and proportioning are investigated
The dried cream powder (extract that embodiment 1 obtains) of crossing No. 4 sieves is pressed different mixed with different adjuvants, use the ethanol moistening, make soft material, granulate with 18 mesh sieves.The results are shown in Table 5:
Ratio of adjuvant that table 5 is different and result
| Dried cream and ratio of adjuvant | The result | |
| 1 | Dried cream: microcrystalline Cellulose (7: 3) | Soft material is clamminess a bit, sticking sieve during granulation |
| 2 | Dried cream: dextrin (7: 3) | Soft material is clamminess, and little lump is arranged, and can not granulate |
| 3 | Dried cream: starch (7: 3) | Soft material is clamminess, and little lump is arranged, and can not granulate |
| 4 | Dried cream: microcrystalline Cellulose: starch (5: 3: 2) | Soft material is not clamminess, and is very loose, and it is very smooth to granulate |
| 5 | Dried cream: microcrystalline Cellulose: dextrin (5: 3: 2) | Soft material is not clamminess, and is very loose, and it is very smooth to granulate |
| 6 | Dried cream: starch (1: 1) | Soft material is clamminess than some with No. 4, but can granulate, slightly some sticking sieve |
| 7 | Dried cream: microcrystalline Cellulose: starch (6: 3: 1) | Soft material is not clamminess, and is loose, can granulate |
| 8 | Dried cream: microcrystalline Cellulose: starch (6.5: 3: 0.5) | Granulating, some glues sieve |
| 9 | Dried cream: micropowder silica gel (9.9: 0.1) | Soft material becomes lump, can not granulate |
| 10 | Dried cream: micropowder silica gel (9.5: 0.5) | Soft material becomes lump, can not granulate |
| 11 | Dried cream: microcrystalline Cellulose: micropowder silica gel (6.9: 3: 0.2) | Soft material is clamminess, the sticking sieve of granulating |
2, the mensuration of bulk density
Granule after sieving is put into exsiccant 10ml graduated cylinder, be vibrated to scale gently, then the granule in the graduated cylinder is weighed as M (g), both ratio is bulk density.Bulk density=M/V the results are shown in Table 6:
The bulk density of each sample of table 6
| Sample number | Bulk density (g/ml) |
| 4 | 0.321 |
| 5 | 0.318 |
| 6 | 0.346 |
| 7 | 0.329 |
3, the mensuration of angle of repose
Adopt the fixed funnel method, with the series connection of 2 funnels and be fixed in the height place of 2cm on the graph paper of horizontal positioned, carefully granule is poured into along hopper walls in the funnel of going up most till the granule cone tip that forms on the graph paper touches bell mouth, measure the diameter (2R) of conical base by graph paper, calculate tga=H/R angle of repose.Do calculating mean value 3 times.The results are shown in Table 7:
The angle of repose of each sample of table 7
| Sample | Angle of repose |
| 4 | 28.75 |
| 5 | 28.88 |
| 6 | 28.84 |
| 7 | 30.38 |
4, critical relative humidity determines
The mensuration of balance Moisture absorption time: take by weighing the about 1g of sample respectively 4,6, No. 7, be tiled in the weighing bottle that is dried to constant weight, be dried to constant weight, precision steelyard is fixed, opens bottle cap, puts in the glass exsiccator that fills the sodium chloride supersaturated solution (relative humidity is 75.3%), preserve in 25 ℃ of constant temperature, respectively at 2,4,8,12,18,24,36,48,60,72,96h takes out the weighing bottle, precision steelyard decide weight, the calculating hydroscopicity.4 duplicate samples all reach moisture equilibrium at dry side at 72h as a result.
The mensuration of critical relative humidity: take by weighing sample respectively 4,6, No. 7, every part of about 1g is tiled in the weighing bottle that is dried to constant weight, is dried to constant weight, precision steelyard is fixed, open bottle cap, put in the glass exsiccator that fills different salt supersaturated solutions, place in 25 ℃ constant temperature and preserve 72h, take out the weighing bottle, precision steelyard is decided weight, calculates hydroscopicity, the results are shown in Table 8.With hydroscopicity to relative humidity map the moisture equilibrium at dry side curve, see accompanying drawing 1,2,3.
Table 8 critical relative humidity measurement result
By above each figure as can be known, No. 4 sample critical relative humiditys are about 70%, No. 6 sample critical relative humidity and are about 75%, No. 7 sample critical relative humidity and are about 60%.
Conclusion: according to each above test data, consider big production cost of actual industry and dose, determine that optimum preparations shaping technology is: dried cream: microcrystalline Cellulose: starch (6: 3: 1), use the ethanol moistening, according to the dosage form difference, adopt different mesh sieves to granulate.
Experimental example 3 Chinese medicine extract of the present invention are to the influence of mouse brain ischemia
1 experiment purpose
Investigate Chinese medicine extract of the present invention causes the mouse brain anoxia model to the tail vein injection peroxide influence.
2 experiment materials
2.1 tried thing
Provide lot number by natural drug research and development department of China Pharmaceutical Research ﹠ Development Center Co., Ltd: 20080303.
No. 1 medicinal liquid (50% alcohol extraction): yellowish-brown liquid 200ml ,-20 ℃ of preservations are faced the time spent back that thaws and are used (an amount of with distilled water, finally be made into contain raw medicinal herbs 66mg/ml).
No. 2 medicinal liquids (water is carried): yellowish-brown liquid 200ml ,-20 ℃ of preservations are faced the time spent back that thaws and are used (containing raw medicinal herbs 66mg/ml).
No. 3 medicinal liquids (70% alcohol extraction): yellowish-brown liquid 200ml ,-20 ℃ of preservations, face the time spent thaw the back use (use embodiment 1 preparation that gets dry extract, an amount of with distilled water, finally be made into contain raw medicinal herbs 66mg/ml).
No. 4 medicinal liquids (fine powder-medical material crude drug powder): yellow-white fine powder 40g, room temperature preserve, and face the time spent to be mixed with desired concn (containing raw medicinal herbs 66mg/ml) with 0.5%CMC and to irritate stomach and give animal.
2.2 medicine and reagent
T-butyl hydroperoxide: Chemical Reagent Co., Ltd., Sinopharm Group, yellow transparent shape liquid, the inflammable explosive article stow away from heat, kindling material is in the shady and cool ventilation place and preserves.Lot number T20060822.
Hydrogen peroxide: Chemical Reagent Co., Ltd., Sinopharm Group, colourless transparent liquid, content 30%, colourless transparent liquid, lot number 20070907.
Troxerutin sheet: Beijing pharmaceutical Co. Ltd of Daheng, tablet, specification: 60mg/ sheet.Facing the time spent grinds to form behind the medicated powder and to be mixed with desired concn (60mg/ml) with 0.5%CMC and to irritate stomach and give animal.Lot number: 071214.
2.3 laboratory animal
60 of SPF level ICR mices, male and female half and half, body weight 18～22g; Animal is provided by Beijing Vital River Experimental Animals Technology Co., Ltd., licence numbering: SCXK (capital) 2007-0001.
3 experimental techniques
3.1 experimental principle
The interior high oxidation state of the blood that utilizes tail vein injection peroxide and anoxia to cause causes the outbreak of mice TIA sample to be animal model, observes the treatment and the protective effect of Chinese medicine extract of the present invention.
3.2 experimentation
Get 60 of body weight 18～22g SPF level ICR mices, male and female half and half are divided into 7 groups at random: 1. positive controls; 2. model control group; 3.～7. No. 1 medicinal liquid of test sample, No. 2 medicinal liquids, No. 3 medicinal liquids, No. 4 medicinal liquids.Positive controls is irritated the troxerutin solution that stomach gives 300mg/kg, and blank group is given the equivalent lyase, and each administration group is given the need testing solution (dosage is respectively 6g/kg) of 20% (volumetric usage), administration 5d, 2 times/d respectively.
Administration 6d, behind administration 30min, adopt the method for tail vein injection peroxide (t-butyl hydroperoxide/hydrogen peroxide), the 24 hours administration 7.5ml/kg in every interval, behind the tail intravenously administrable, observe 10min, again mice being placed volume is that the sealed container of 500ml is observed 15min, and successive administration is also observed 4d, 1 time/d.Observe the TIA sample outbreak of the reaction of animals after the administration and to its scoring, write down the mortality rate after the administration simultaneously.Standards of grading table 9:
Table 9 TIA sample outbreak standards of grading
| Reaction symptom | Score value |
| The apoplexy index | |
| Hair is dirty and messy, and sounding trembles | 1 |
| Motion descends or is blunt or strong excessively | 1 |
| The ear hypopselaphesia | 1 |
| Perk | 3 |
| Eyeball fixedly shape is opened | 3 |
| Hind leg is " eight " word | 3 |
| The ptosis | 1 |
| Turn-take | 3 |
| The outburst sample of fainting from fear moves | 3 |
| The extreme exhaustion | 6 |
| The neurological symptom activity |
| Spontaneity is probed into | 1 |
| Walk about during stimulation or creep | 1 |
| Inactive during stimulation | 2 |
| | |
| Normally | |
| 0 | |
| Ataxia/muscular tension height | 1 |
| Creep | 2 |
| No gait | 3 |
| Feed | |
| Have | 0 |
| Do not have | 1 |
| Drinking-water | |
| Have | 0 |
| Do not have | 1 |
| Reaction to the pain stimulation | |
| Move/walk about | 0 |
| Head/trunk hypermotility or reaction | 1 |
| Limbs retraction or reactionless | 2 |
| Total points | 39 |
4 experimental results
Experimental result shows: Chinese medicine extract of the present invention causes after to the tail vein injection peroxide outbreak of mice TIA sample for animal model the certain protection effect to be arranged; four medicines all have certain inhibitory action to the TIA sample outbreak symptom of animal pattern; be reflected at its symptom score and all be lower than corresponding model group; wherein 2～No. 4 medicinal liquids are the most obvious to the inhibitory action of this reaction; the reduction of its reaction symptom scoring and the equal significance of model group; and significant difference (P＜0.05) is relatively arranged with model group, wherein obvious with No. 3 medicines and No. 4 drug effects.Experimental result sees Table 10.
Judge from the case fatality rate of animal that simultaneously the case fatality rate of four medicine groups all is lower than model group, wherein the effect with No. 3 medicines and No. 4 medicines is the most obvious.Experimental result sees Table 11.
Symptom score statistical table after the table 10 Chinese medicine extract administration of the present invention
Compare with model group,
*P＜0.05,
*P＜0.01
Case fatality rate statistical table after the table 11 Chinese medicine extract administration of the present invention
5 conclusions
4 cause after to the tail vein injection peroxide outbreak of mice TIA sample for animal model the certain protection effect to be arranged all for test agents, and wherein the effect with No. 3 medicines and No. 4 medicines is the most obvious.
Experimental example 4
1 experiment purpose
To extract oral capsule of the present invention, carry out the pharmacodynamic experiment comparative study, to determine whether this product is oral effective.
2 experiment materials
2.1 tried thing
Provide lot number by Mudanjiang friend pharmaceutical factory of fighting: 070731;
Test sample A: two bottles of Hirudo, Pheretima oligopeptide liquid, dark brown liquid, crude drug content is respectively 0.81g/ml and 1.4g/ml, faces the time spent to be mixed with desired concn with distilled water, 4 ℃ of preservations.
Test sample B: SHUXUETONG ZHUSHEYE, yellow transparent shape liquid, crude drug content is 0.5g/ml, faces the time spent to be mixed with desired concn with distilled water, 4 ℃ of preservations.
Test sample C: embodiment 6 gained capsules (call in the following text dredge blood open capsule) face the time spent to be mixed with desired concn with 0.5%CMC (carboxymethyl cellulose), 4 ℃ of preservations.
Test sample D: Hirudo, Pheretima residue powder, dark gray powder, crude drug content is 11g/g, faces the time spent to be mixed with desired concn with 0.5%CMC, 4 ℃ of preservations.
2.2 medicine and reagent
Prothrombin time (PT) is measured test kit: Shanghai Sun Bio-Tech Co., Ltd., lot number: 105053
Thrombin time (TT) is measured test kit: Shanghai Sun Bio-Tech Co., Ltd., lot number: 121018
Aspirin (ASP): white powder, the omnipotent pharmaceutical factory in Shenyang produces lot number: 20020808
ADP:sigma import packing, lot number: 073K7007
2.3 instrument
QX-200 whole blood platelet aggregation instrument: Instrument Factory of Shanghai Medical Univ.
2.4 animal
100 of SPF level ICR mices, male and female half and half, body weight 18～22g; 200 of SPF level male SD rats, body weight 250～300g; Animal is provided by Beijing Vital River Experimental Animals Technology Co., Ltd., licence numbering: SCXK (capital) 2007-0001.
3 experimental techniques
3.1 dredge of the influence of blood open capsule to the mice blood coagulation system
Get 100 of body weight 18～22g SPF level ICR mices, male and female half and half are divided into ten groups at random: 1. positive controls; 2. blank group; 3.～10. test sample A, B, the high low dose group of C, D.Positive controls is irritated the ASP solution that stomach gives 100mg/kg, blank group is given the equivalent lyase, and the high low dosage group of each administration group gives the need testing solution of 20% and 5% (dosage is respectively 6g/kg and 1.5g/kg) respectively, and the administration volume is 15ml/kg, administration 7d, 2 times/d.Behind the d7 administration 30min, after utilizing tail vein blood to measure clotting time (CT), every animal eye socket blood sampling 0.8～1ml adds in the centrifuge tube of the minor official sour sodium of Chinese holly that 0.109M is housed, behind the centrifugal 10min of 3000rmp/min, get blood plasma and detect prothrombin time (PT) and thrombin time (TT), the results are shown in Table 12.
3.2 dredge of the influence of blood open capsule to the rat blood coagulation system
Get 100 of body weight 250～300g SPF level SD male rats, be divided into ten groups at random: 1. positive controls; 2. blank group; 3.～10. test sample A, B, the high low dose group of C, D.Positive controls is irritated the ASP solution that stomach gives 70mg/kg, blank group is given the equivalent lyase, and the high low dosage group of each administration group gives the need testing solution of 20% and 5% (dosage is respectively 4.0g/kg and 1.0g/kg) respectively, and the administration volume is 10ml/kg, administration 7d, 2 times/d.
Before the administration, animal eye socket vein is got blood 2～3ml, behind the mensuration clotting time (CT), 0.8～1ml blood is sub-packed in the centrifuge tube of the minor official sour sodium of Chinese holly that 0.109M is housed, behind the centrifugal 10min of 3000rmp/min, get blood plasma and detect prothrombin time (PT) and thrombin time (TT).
Behind the d7 administration 30min, after animal eye socket vein is got hematometry clotting time (CT), every animal eye socket blood sampling 0.8～1ml adds in the centrifuge tube of the minor official sour sodium of Chinese holly that 0.109M is housed, behind the centrifugal 10min of 3000rmp/min, get blood plasma and detect prothrombin time (PT) and thrombin time (TT), the results are shown in Table 13,14.
3.3 dredge the influence of the rat platelet aggregation that the blood open capsule causes ADP
Get 100 of body weight 250～300g SPF level SD male rats, be divided into ten groups at random: 1. positive controls; 2. blank group; 3.～10. test sample A, B, the high low dose group of C, D.Positive controls is irritated the ASP solution that stomach gives 70mg/kg, blank group is given the equivalent lyase, and the high low dosage group of each administration group gives the need testing solution of 20% and 5% (dosage is respectively 4.0g/kg and 1.0g/kg) respectively, and the administration volume is 10ml/kg, administration 7d, 2 times/d.
Behind the d7 administration 30min, after animal eye socket vein is got hematometry clotting time (CT), continue to get blood 0.8～1.0ml and be sub-packed in generation survey in the centrifuge tube that the 200U/ml heparin is housed.During experiment, get the 0.5ml blood sample and add in the proprietary test tube, the quantitative pipettor of reuse adds the tyrode of 0.5ml in blood sample, behind 37 ℃ of incubation 5min, adds the ADP solution 5 μ l of 1mmol/L, observes the maximum aggregation extent in the 5min.Write down the platelet aggregation degree of 30s, 60s, 90s respectively, and record reaches the time point and the time point that reaches 1/2 maximum aggregation extent of maximum aggregation extent.The platelet aggregation test of all samples is all finished in 4h.
The preparation of tyrode (pH=7.4): get NaCl 8.0g, MgCl
26H
2O 0.427g, CaCl
20.2g, KCl 0.2g, glucose 1g, NaHCO
31.5g, NaH
2PO
4.2H
2O0.065g, heparin 2000U are settled to 1000ml with distilled water, are the special-purpose buffer solution of this experiment, 4 ℃ of preservations.The results are shown in Table 15.
3.4 dredge of the influence of blood open capsule to the rat vein thrombosis
Get 100 of body weight 250～300g SPF level SD male rats, be divided into ten groups at random: 1. positive controls; 2. blank group; 3.～10. test sample A, B, the high low dose group of C, D.Positive controls is irritated the ASP solution that stomach gives 70mg/kg, blank group is given the equivalent lyase, and the high low dosage group of each administration group gives the need testing solution of 20% and 5% (dosage is respectively 4.0g/kg and 1.0g/kg) respectively, and the administration volume is 10ml/kg, administration 8d, 2 times/d.
Behind the d8 administration 30min, 3.5% chloral hydrate (10ml/kg, ip) open abdomen behind the anesthetized animal, separate postcava, with left renal vein below surgical thread ligation postcava, sew up stomach wall, reopen the abdominal cavity behind 2h, the 6h, removal of thromboses claims weight in wet base, 60 ℃ of dry 4h after removing floating blood, the cooling back claims dry weight, calculates thrombus weight and thrombosis suppression ratio.The results are shown in Table 16,17.
Table 12 dredge the blood open capsule to the influence of mice blood coagulation system (x ± s, n=10)
Compare with blank,
*P＜0.05,
*P＜0.01.
Table 13 is dredged the influence of blood open capsule to the rat blood coagulation system
Measured value before the administration (x ± s, n=10)
Compare with blank,
*P＜0.05,
*P＜0.01
Table 14 dredge the blood open capsule to the influence administration of rat blood coagulation system after measured value
(x±s，n＝10)
Compare with blank,
*P＜0.05,
*P＜0.01
Table 15 is dredged the influence of blood open capsule to rat platelet aggregation
(x±s，n＝10)
Compare with blank,
*P＜0.05,
*P＜0.01
Table 16 is dredged the influence of blood open capsule to rat postcava ligation 2h posterior vein thrombosis
(x±s，n＝10)
Compare with blank,
*P＜0.05,
*P＜0.01
Table 17 is dredged the influence of blood open capsule to rat postcava ligation 6h posterior vein thrombosis
(x±s，n＝10)
Compare with blank,
*P＜0.05,
*P＜0.01
Experimental result:
Capsule of the present invention is to the significantly influence that has of blood coagulation system: the clotting time to mice and rat has significantly prolongation effect, and to the thrombin time (TT) of rat, significantly prolongation effect is arranged; The rat platelet aggregation that ADP is caused all has than the obvious suppression effect; All more obvious to the thrombotic inhibitory action of rat vein.
Claims (6)
1. oral formulations for the treatment of the Chinese medicine extract of apoplexy and cardiovascular disease, wherein contain Chinese medicine extract, it is characterized in that it is crude drug that this extract is selected Hirudo and Pheretima for use, and be: water intaking trematodiasis, each 50g of Pheretima by following method preparation, with 500g, volumetric concentration is 70% ethanol extraction 2 times, each 1.5h filters, and reclaims filtrate, concentrate, get dry extract.
2. according to the oral formulations of the described Chinese medicine extract of claim 1, it is characterized in that it comprises the component of following weight ratio: dried cream: microcrystalline Cellulose: starch is 6: 3: 1.
3. according to the oral formulations of the described Chinese medicine extract of claim 1, it is characterized in that described preparation is capsule, granule, tablet or drop pill.
4. according to the oral formulations of the described Chinese medicine extract of claim 3, described capsule is a soft capsule.
5. according to the oral formulations of the described Chinese medicine extract of claim 3, described tablet is oral cavity disintegration tablet, chewable tablet or dispersible tablet.
6. a method for preparing as oral formulations as described in the claim 2 is characterized in that, comprises the steps: dried cream powder and microcrystalline Cellulose, starch are mixed in proportion, and uses the ethanol moistening, makes soft material, granulates with suitable mesh sieve.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100797605A CN101829148B (en) | 2009-03-10 | 2009-03-10 | Traditional Chinese medicine extractive, oral preparation containing extractive and method for preparing oral preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100797605A CN101829148B (en) | 2009-03-10 | 2009-03-10 | Traditional Chinese medicine extractive, oral preparation containing extractive and method for preparing oral preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101829148A CN101829148A (en) | 2010-09-15 |
| CN101829148B true CN101829148B (en) | 2011-09-07 |
Family
ID=42713469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100797605A Active CN101829148B (en) | 2009-03-10 | 2009-03-10 | Traditional Chinese medicine extractive, oral preparation containing extractive and method for preparing oral preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101829148B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101972279B (en) * | 2010-11-05 | 2012-07-25 | 王家辉 | External traditional Chinese medicine for treating cerebral thrombosis |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101966226B (en) * | 2010-10-08 | 2011-09-28 | 张继成 | Chinese medicinal composition for treating heart cerebrovascular diseases |
| CN110075222A (en) * | 2019-05-17 | 2019-08-02 | 王兴东 | A kind of logical Chinese materia medica preparation of heart and brain |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1216255A (en) * | 1998-09-30 | 1999-05-12 | 张明玉 | Preparation of ethanol extracted earthworm tissue liquid |
| CN1559474A (en) * | 2004-03-10 | 2005-01-05 | 张正生 | Chinese medicinal preparation of anti embolus disease and its preparation method |
| CN1857321A (en) * | 2006-03-21 | 2006-11-08 | 陈志成 | Preparing method of blood circulation promoting injection |
| CN101433586A (en) * | 2008-12-05 | 2009-05-20 | 泸州医学院附属中医医院 | Medicament for treating ischemic cerebrovascular disease and preparation method thereof |
-
2009
- 2009-03-10 CN CN2009100797605A patent/CN101829148B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1216255A (en) * | 1998-09-30 | 1999-05-12 | 张明玉 | Preparation of ethanol extracted earthworm tissue liquid |
| CN1559474A (en) * | 2004-03-10 | 2005-01-05 | 张正生 | Chinese medicinal preparation of anti embolus disease and its preparation method |
| CN1857321A (en) * | 2006-03-21 | 2006-11-08 | 陈志成 | Preparing method of blood circulation promoting injection |
| CN101433586A (en) * | 2008-12-05 | 2009-05-20 | 泸州医学院附属中医医院 | Medicament for treating ischemic cerebrovascular disease and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 何红 等."地龙提取物的抗凝血作用".《中草药》.2007,第38卷(第5期),第733-735页. |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101972279B (en) * | 2010-11-05 | 2012-07-25 | 王家辉 | External traditional Chinese medicine for treating cerebral thrombosis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101829148A (en) | 2010-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100453105C (en) | Composition with catharsis and toxin expelling, fat reducing and weight reducing function and preparing method | |
| CN102362881A (en) | Method for preparing ginkgo and American ginseng preparation | |
| CN101940740A (en) | Chinese medicinal preparation for treating anemia and preparation method thereof | |
| CN101502627A (en) | Chinese medicine health product preparation for preventing and treating alcoholic liver disease and preparation method thereof | |
| CN101829148B (en) | Traditional Chinese medicine extractive, oral preparation containing extractive and method for preparing oral preparation | |
| CN1923241B (en) | Medicine composition containing epimedium extract, uncaria extract, and gastrodine, and its preparation and use | |
| CN107569612A (en) | A kind of medicine for improving sleep and preparation method thereof | |
| CN102258742A (en) | Chinese medicinal medicine composition for treating depression and preparation method thereof | |
| CN101711809A (en) | Medicine composition for treating postpartum melancholia, preparation method and application | |
| CN1857385B (en) | Medicine composition for treating cervical spondylosis and its preparing method | |
| CN1958010A (en) | Composition preparation of Chinese traditional medicine, and preparation method | |
| CN1840087B (en) | King solomonseal- and fleece-flower root-containing Chinese medicinal formulation for treating chronic fatigue syndrome and its preparation method | |
| CN105434738A (en) | Traditional Chinese medicine composition for treating ADHD (Attention Deficit Hyperactivity Disorder) and preparation method thereof | |
| CN100360153C (en) | Glucoside extracts from figwort roof, its making method and use in preparing medicines | |
| CN1857627B (en) | Apoplexy treating Chinese medicine preparation and its preparing process | |
| CN101947299B (en) | Medicinal composition for treating coronary heart disease | |
| CN1935171A (en) | Medicinal composition and its preparing method | |
| CN1891255B (en) | Blood total flavone extract, and its preparing method and use | |
| CN1318034C (en) | Drug prepared by mulberry bark extract | |
| CN1935198A (en) | Chinese medicine compound preparation and its preparing method | |
| CN103007030B (en) | Preparation method of Chinese medicinal composition and preparation for preventing and treating male infertility | |
| CN101708252B (en) | Compound Chinese medicinal preparation for treating lung cancer and preparation method thereof | |
| CN101152247A (en) | Pharmaceutical composition for cardiovascular and cerebrovascular diseases and method for preparing the same | |
| CN1315857C (en) | Preparation of Chinese medicine clinopodium polycephalum saponin | |
| CN101269115A (en) | Cardiac and cerebral vascular disease treating medicament preparation and method for preparing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: MUDANJIANG YOUBO PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: LI ZHENGUO Effective date: 20120117 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100027 CHAOYANG, BEIJING TO: 157011 MUDANJIANG, HEILONGJIANG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20120117 Address after: 157011 No. 6 cultural street, Aimin Road, Heilongjiang, Mudanjiang Patentee after: Mudanjiang Youbo Pharmaceutical Co.,Ltd. Address before: 100027 Beijing city Chaoyang District Xinyuanli Kun Sha center A block 2101 Patentee before: Li Zhenguo |
|
| C56 | Change in the name or address of the patentee | ||
| CP03 | Change of name, title or address |
Address after: 157011, 6, culture street, Aimin District, Heilongjiang, Mudanjiang Patentee after: Mudanjiang Youbo Pharmaceutical Co., Ltd. Address before: 157011 No. 6 cultural street, Aimin Road, Heilongjiang, Mudanjiang Patentee before: Mudanjiang Youbo Pharmaceutical Co.,Ltd. |
|
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: 157013 Heilongjiang province Mudanjiang City Yangming District Yumin Road No. 288 Patentee after: Mudanjiang Youbo Pharmaceutical Co., Ltd. Address before: No. 6, cultural street, Aimin District, Mudanjiang, Heilongjiang, China Patentee before: Mudanjiang Youbo Pharmaceutical Co., Ltd. |
|
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 157013 Heilongjiang province Mudanjiang City Yangming District Yumin Road No. 288 Patentee after: Mudanjiang Youbo Pharmaceutical Co.,Ltd. Address before: 157013 Heilongjiang province Mudanjiang City Yangming District Yumin Road No. 288 Patentee before: Mudanjiang Youbo Pharmaceutical Co., Ltd. |